|
Citius Oncology Inc (NASDAQ: TENKU) |
|
Citius Oncology Inc
TENKU's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Citius Oncology Inc 's sales fell
in II. Quarter 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 5.17 %
Citius Oncology Inc 's net profit decreased by -59.04 % in II. Quarter 2024 year on year, to $0 millions.
• More on TENKU's Growth
|
|
Citius Oncology Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Citius Oncology Inc realized cash reduction of $ -0.09 per share in trailing twelve-month period. |
Company |
194.84 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.23.
• More on TENKU's Valuation
|
|
|
|
|
Citius Oncology Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Citius Oncology Inc realized cash outflow of $ -0.09per share in trailing twelve-month period. |
Company |
194.84 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.23.
• More on TENKU's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com